{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:19:30Z","timestamp":1783423170048,"version":"3.54.6"},"reference-count":15,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":187,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Case Reports in Dermatological Medicine"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Deucravacitinib is an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of moderate\u2010to\u2010severe plaque psoriasis and psoriatic arthritis. Deucravacitinib may offer a more selective approach compared to traditional Janus kinase (JAK) inhibitors. Emerging data support the use of deucravacitinib in inflammatory dermatoses beyond psoriatic disease. We present our clinical experience using deucravacitinib off\u2010label in patients with challenging inflammatory skin disease and contextualize our findings within the current literature. We report three female patients aged 31\u201363\u2009years with refractory inflammatory skin conditions, including two with dermatomyositis and one with pityriasis rubra pilaris (PRP). All patients had persistent disease despite multiple systemic therapies, such as oral corticosteroids (OCS), acitretin, azathioprine, mycophenolate mofetil (MMF), JAK inhibitors, intravenous immunoglobulin (IVIG), and\/or rituximab. Deucravacitinib 6\u2009mg daily was initiated as adjunctive or alternative therapy. Both patients with dermatomyositis experienced meaningful cutaneous improvement; one also demonstrated improved proximal muscle strength and a sustained response over 2\u2009years without adverse events. The other showed gradual resolution of facial erythema but developed a mild acneiform eruption. The patient with PRP achieved marked improvement by 6\u2009months and near\u2010complete remission by 10 months, without reported adverse events. This case report supports the potential efficacy and adequate tolerability of deucravacitinib as an off\u2010label option for refractory inflammatory dermatoses, specifically dermatomyositis and PRP. Larger prospective studies are needed to better define its long\u2010term safety and therapeutic role beyond psoriasis.<\/jats:p>","DOI":"10.1155\/crdm\/9941426","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:06:05Z","timestamp":1783422365000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Off\u2010Label Uses of Deucravacitinib for Inflammatory Skin Conditions: Cases and Literature Review"],"prefix":"10.1155","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1247-407X","authenticated-orcid":false,"given":"Alexandra","family":"Nigro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6627-7182","authenticated-orcid":false,"given":"Isabel C.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7750-5957","authenticated-orcid":false,"given":"Benjamin","family":"Gerstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4899-1724","authenticated-orcid":false,"given":"Jasper","family":"Dayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5295-8726","authenticated-orcid":false,"given":"Saakshi","family":"Khattri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"e_1_2_8_1_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.005"},{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/24755303231201336"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106642"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00596-8"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26199447"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-026-01742-w"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084301"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X221093453"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/life14080923"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2025.01.047"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2025.10.010"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000548207"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01093-w"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.5224"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1752884"}],"container-title":["Case Reports in Dermatological Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/crdm\/9941426","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/crdm\/9941426","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/crdm\/9941426","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:06:06Z","timestamp":1783422366000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/crdm\/9941426"}},"subtitle":[],"editor":[{"given":"Semonti","family":"Nandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1155\/crdm\/9941426"],"URL":"https:\/\/doi.org\/10.1155\/crdm\/9941426","archive":["Portico"],"relation":{},"ISSN":["2090-6463","2090-6471"],"issn-type":[{"value":"2090-6463","type":"print"},{"value":"2090-6471","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2026-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"9941426"}}